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Toward a Better Understanding of...
Time-Dependent Effects of  apoE Reduction 
Using Antisense Oligonucleotides 
in a Model of  β-amyloidosis
Caroline Francis
Mentors: David Holtzman and Phat Huynh
Extensive clinical studies have established the Apolipoprotein E (APOE) gene on 
chromosome 19 as the strongest genetic risk factor for late-onset Alzheimer disease 
(AD). Using human APOE knock-in mice, it was previously demonstrated that Apoe-
hemizygous APP/PS1 mice have significantly less amyloid plaque deposition and 
microglial activation compared to their homozygous littermates. Since apoE levels were 
lower in Apoe hemizygous mice for their entire life, it was not clear from a mechanistic and 
therapeutic perspective whether lowering apoE levels pharmacologically in adult animals 
would affect amyloid deposition. Here, we utilize an apoE antisense oligonucleotide 
(ASO) to reduce apoE expression in the adult APP/PS1-21 mice homozygous for the 
human ε4 allele of APOE. Despite achieving reduction of apoE expression by more 
than 50% starting at the onset of amyloid deposition, no reduction of Aβ pathology 
is detected when mice were assessed at four months of age. Though there was not an 
overall reduction in amyloid deposition, there was a clear effect of reducing apoE4 on 
Aβ plaque morphology. Interestingly, ASO treatment starting after birth led to a strong 
and significant decrease in Aβ pathology when mice were assessed at four months of age. 
These results suggest that apoE levels can strongly affect the initiation of Aβ pathology in 
vivo but that once Aβ plaque pathology is present, reducing apoE does not have a strong 
effect on further amyloid deposition. This previously unknown age-dependent effect 
of apoE in the early stages of Aβ plaque formation suggest the important implication 
that decreasing brain apoE levels would be useful for primary prevention of amyloid 
deposition but not for decreasing or removing amyloid plaques once they have begun 
depositing.
